NovoMatrix in Gingival Recession Coverage: Case Series
Safety and Efficacy of NovoMatrix in Gingival Recession Coverage /A Pilot Clinical and Histological Case Series/
Semmelweis University
20 participants
May 5, 2024
INTERVENTIONAL
Conditions
Summary
Twenty patients seeking treatment for gingival recession coverage, ranging from 20-70 years of age with multiple Miller Class I or II buccal gingival recessions (depth≥3 mm, at least 3 adjacent teeth) will be recruited for this study. Five patients within the study patient pool looking for further orthodontic or restorative treatment that requires removal of one single rooted tooth within the study site of interest will be selected for histological sample removal. All procedures performed in this study will be executed according to established routine protocols, with the exception of block biopsies of one hopeless tooth per patient (total of 5 patients) at 6 months.
Eligibility
Inclusion Criteria14
- Male or female, between 20-70 years of age, who request gingival augmentation or recession coverage.
- Subjects who are willing to sign an informed consent, participate and return for follow-up visits.
- Subjects without significant medical history and currently not on medications that might complicate treatment outcomes.
- Subjects demonstrating good oral hygiene (FMPS, FMBS less than 20%).
- Subjects who received and failed a previously placed autogenous graft.
- Subjects who have significant untreated periodontal disease, caries, infection or chronic inflammation in the oral cavity within two adjacent tooth positions of the clinical trial area.
- Subjects who have used nicotine-containing products within 3 weeks prior to surgery.
- Subjects who are insulin-dependent diabetic or if their Hgb1c levels \> 6.5%.
- Subjects who have had a history of malignancy within the past 5 years (except for basal or squamous cell carcinoma of the skin or in situ cervical carcinoma).
- Subjects who are nursing or pregnant.
- Subjects who are presently taking medications (except estrogen/progesterone therapy) or those who are undergoing treatment that in known to have an effect on bone turnover.
- Subjects who have diseases that affect bone metabolism (excluding idiopathic osteoporosis).
- Subjects with a history of an autoimmune disease, documented allergy or multiple allergies to any component of the agents used in this study.
- Acutely infected mucogingival defect site.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06409468